Related Experiment Videos
Phospholipase A2 activity modulates "ischemic effect" in pig skin
Abstract:
The level of cyclic AMP in the epidermis rapidly increase within 15 min after separation from the in vivo condition. This phenomenon is the so-called "ischemic effect." In order to elucidate the possible mechanism of the ischemic effect, the effects of melittin and mepacrine on the ischemic condition of the skin were studied. Melittin, a stimulator of phospholipase A2, lessened the increase of cyclic AMP, while mepacrine, an inhibitor of phospholipase A2, potentiated the increase of cyclic AMP during the ischemic condition. The overall results suggest that phospholipase A2 may play an important role in the induction of the ischemic condition through membrane alteration.
Insights
The skin
Area of Science:
- Dermatology
- Biochemistry
Background:
- The epidermis exhibits a rapid increase in cyclic AMP levels upon separation from in vivo conditions, known as the 'ischemic effect'.
- The precise molecular mechanisms underlying this ischemic effect require further elucidation.
Purpose of the Study:
- To investigate the role of phospholipase A2 in the epidermal ischemic effect.
- To explore the impact of melittin and mepacrine on cyclic AMP levels during skin ischemia.
Main Methods:
- Studied the effects of melittin (a phospholipase A2 stimulator) and mepacrine (a phospholipase A2 inhibitor) on isolated skin.
- Measured cyclic AMP levels in the epidermis under ischemic conditions.
Main Results:
- Melittin treatment attenuated the rise in cyclic AMP levels during ischemia.
- Mepacrine treatment potentiated the increase in cyclic AMP levels during ischemia.
- These findings implicate phospholipase A2 activity in the ischemic response.
Conclusions:
- Phospholipase A2 activity appears to be a key factor in inducing the epidermal ischemic effect.
- Membrane alterations mediated by phospholipase A2 may contribute to the observed changes in cyclic AMP levels.